Nature Reviews Neurology, Год журнала: 2023, Номер 19(9), С. 509 - 510
Опубликована: Июль 25, 2023
Язык: Английский
Nature Neuroscience, Год журнала: 2024, Номер 27(3), С. 471 - 483
Опубликована: Янв. 30, 2024
Язык: Английский
Процитировано
20
Multiple Sclerosis Journal, Год журнала: 2023, Номер 29(4-5), С. 585 - 594
Опубликована: Фев. 1, 2023
Background Data are sparse regarding the safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (MS). Objective To estimate (1) pooled proportion MS experiencing relapse among vaccine recipients; (2) rate transient neurological worsening, adverse events, and serious events; (3) previous outcomes interest for different SARS-CoV-2 types. Methods Systematic review meta-analysis pharmacovigilance registries observational studies. Results Nineteen studies comprising 14,755 who received 23,088 doses COVID-19 were included. Mean age was 43.3 years (95% confidence interval (CI): 40–46.6); relapsing-remitting, secondary-progressive, primary-progressive clinically isolated diagnosed 82.6% CI: 73.9–89.8), 12.6% 6.3–20.8), 6.7% 4.2–9.9), 2.9% 1–5.9) cases, respectively. The at a mean time 20 days 12–28.2) from vaccination 1.9% 1.3%–2.6%; I = 78%), risk being independent type administered SARS-CoV-2-vaccine ( p subgroup differences 0.7 messenger RNA (mRNA), inactivated virus, adenovector-based vaccines). After vaccination, worsening observed 4.8% 2.3%–8.1%) patients. Adverse events reported 52.8% 46.7%–58.8%) 0.1% 0%–0.2%) vaccinations, Conclusion does not appear to increase MS. Weighted against risks SARS-CoV-2-related complications exacerbations, these data provide compelling pro-vaccination arguments
Язык: Английский
Процитировано
35
Multiple Sclerosis Journal, Год журнала: 2023, Номер 29(8), С. 904 - 925
Опубликована: Июнь 9, 2023
Background: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of risk management strategy Objective: To develop a European evidence-based consensus pwMS who are candidates disease-modifying therapies (DMTs). Methods: This work was conducted by multidisciplinary working group using formal methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs vaccines. A systematic literature search quality evidence defined according to Oxford Centre Evidence-Based Medicine Levels Evidence. The recommendations were formulated based on risk–benefit balance. Results: Seven questions, encompassing vaccine safety, effectiveness, global in sub-populations (pediatric, pregnant women, elderly international travelers) considered. narrative description considering published studies, guidelines, position statements is presented. total 53 agreed after three rounds consensus. Conclusion: first proposes best current expert knowledge, goal homogenizing immunization practices pwMS.
Язык: Английский
Процитировано
35
Multiple Sclerosis and Related Disorders, Год журнала: 2025, Номер unknown, С. 106303 - 106303
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
2
Proceedings of the National Academy of Sciences, Год журнала: 2025, Номер 122(7)
Опубликована: Фев. 12, 2025
Primary progressive multiple sclerosis (MS) is a demyelinating autoimmune disease with only single class of FDA-approved treatment, B cell depletion. Novel treatments could emerge from deeper understanding the interplay between types within diseased tissue throughout progression. We initially describe an engineered biomaterial–based immunological niche (IN) as surrogate for to investigate immune function and phenotype dynamics chronic mouse model MS. Using these niches, we identify array dysregulated CC chemokine signaling potential targets. then develop antigen-loaded nanoparticles that reduce signaling, while delivering antigen. These serve antigen-specific injection reduces burden, even if administered after symptomatic onset. This report demonstrates proof principle biomaterial scaffold can monitor function, drug targets, guide development therapeutic.
Язык: Английский
Процитировано
1
The Lancet Neurology, Год журнала: 2025, Номер 24(4), С. 361 - 370
Опубликована: Март 20, 2025
Язык: Английский
Процитировано
1
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Март 9, 2023
Cumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research exploring utility targeting to contain disease activity these disorders. In this review, we first recapitulate development from their origin bone marrow migration periphery, including expression therapy-relevant surface immunoglobulin isotypes. Not only ability produce cytokines immunoglobulins seems be essential driving neuroinflammation, but also regulatory functions strongly impact pathobiology. We then critically assess studies cell depleting therapies, CD20 CD19 monoclonal antibodies, as well new class modulating substances, Bruton´s tyrosinekinase (BTK) inhibitors, MS, NMOSD MOGAD.
Язык: Английский
Процитировано
21
Biomedicines, Год журнала: 2023, Номер 11(9), С. 2489 - 2489
Опубликована: Сен. 8, 2023
This review delves into neuroimmunology, focusing on its relevance to multiple sclerosis (MS) and potential treatment advancements. Neuroimmunology explores the intricate relationship between immune system central nervous (CNS). Understanding these mechanisms is vital for grasping pathophysiology of diseases like MS devising innovative treatments. introduces foundational neuroimmunology concepts, emphasizing role cells, cytokines, blood–brain barrier in CNS stability. It highlights how their dysregulation can contribute discusses genetic environmental factors influencing susceptibility. Cutting-edge research methods, from omics techniques advanced imaging, have revolutionized our understanding MS, offering valuable diagnostic prognostic tools. also touches intriguing gut–brain axis, examining gut microbiota impacts neuroimmunological processes therapeutic implications. Current treatments, immunomodulatory drugs disease-modifying therapies, are discussed alongside promising experimental approaches. The personalized medicine, cell-based gene therapy management explored. In conclusion, this underscores neuroimmunology’s significance research, suggesting that a deeper could pave way more tailored effective treatments similar conditions. Continued collaboration essential enhancing patient outcomes.
Язык: Английский
Процитировано
18
Multiple Sclerosis Journal, Год журнала: 2025, Номер unknown
Опубликована: Март 12, 2025
Background: Vaccination in patients with multiple sclerosis (PwMS) presents unique challenges. Disease-modifying therapies (DMTs) can increase infectious risks, though these are largely preventable through immunizations. However, DMTs also reduce vaccine efficacy. Aims: This study aimed to identify challenges achieving effective immunization for PwMS and explore strategies optimize vaccination practices. Methods: Recent guidelines studies on were reviewed pinpoint challenges, unmet needs, opportunities improvement. Results: Early before DMT initiation is vital optimal responses, coordinating vaccinations DMTs’ Strategies enhance efficacy, such as bridging or more immunogenic formulations, may benefit highly active requiring immediate initiation. Although live-attenuated vaccines pose those immunosuppressive therapies, emerging evidence suggests safe administration select cases. Overcoming hesitancy demands targeted education, personalized counseling, improved access services, especially low- middle-income countries. Inclusivity crucial, particularly groups, pediatric, pregnant, elderly PwMS. Conclusion: A multifaceted approach essential addressing Collaborative efforts involving stakeholders crucial overcoming obstacles generating robust evidence. We propose an integrated strategy ensure while maintaining timely administration.
Язык: Английский
Процитировано
1
European Journal of Neurology, Год журнала: 2023, Номер 30(8), С. 2144 - 2176
Опубликована: Июнь 9, 2023
Abstract Background and purpose With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of risk management strategy. We aimed to develop a European evidence‐based consensus strategy pwMS who are candidates disease‐modifying therapies (DMTs). Methods This work was conducted by multidisciplinary working group using formal methodology. Clinical questions (defined as population, interventions outcomes) considered all authorized DMTs vaccines. A systematic literature search quality evidence defined according Oxford Centre Evidence‐Based Medicine Levels Evidence. The recommendations were formulated based on risk–benefit balance. Results Seven questions, encompassing vaccine safety, effectiveness, global in subpopulations (pediatric, pregnant women, elderly international travelers) considered. narrative description considering published studies, guidelines position statements is presented. total 53 agreed after three rounds consensus. Conclusion first proposes best current expert knowledge, goal homogenizing immunization practices pwMS.
Язык: Английский
Процитировано
13